Pharma Mar Sa · BME:PHM
Pharma Mar Sa — Investor Presentation (October 2025)
26 slides from Pharma Mar Sa's investor presentation, October 2025
Slide 1: Corporate Presentation
October 2025 Corporate Presentation World leader in the development and commercialization of anticancer drugs of marine origin
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity, results of operation, clinical program, plans and objectives of Pharma Mar, S.A. ("PharmaMar" or the "Company"). These f
Slide 3: Our vision
Our vision We are inspired by the sea, driven by science, and motivated to improve the lives of cancer patients by delivering novel medicines. We intend to continue to be the world leader in marine medicinal discovery, development and innovation. 3
Slide 4: Corporate Overview
Corporate Overview Global Fully Integrated 3 Approved Oncology Products Commercial Stage Biotech Developing marine-inspired oncology drugs Established European oncology sales force Revenue Generating & Profitable Revenues 1H 2025 €95.3m Discovery Platform Strengthening Oncology Pipeline EBITDA 1H 20
Slide 5: The Plan for growth
The Plan for growth Continue delivering value to shareholders Lurbinectedin Other drugs Corporate development development development ✦ Looking for in-licensing ✦ Filed in 1L maintenance in SCLC ✦ PM54 in PoC Phase I products to market in the EU and approval in the US. ✦ PM534 in PoC Phase I ✦ Outli
Slide 6: Pipeline – Expanding our Expertise in Oncology
Pipeline – Expanding our Expertise in Oncology Phase 1 Phase 2 Phase 3 Market Soft tissue Sarcoma Monotherapy 2nd/3rd line + PLD (pegylated liposomal Ovarian cancer 2nd/3rd line doxorubicin) R/R Multiple Myeloma1 + dexamethasone 3rd/4th line Small cell lung cancer Monotherapy 2nd line US / other cou
Slide 7: Standard of Care in 2L SCLC in the US
Standard of Care in 2L SCLC in the US Emerging in 1L maintenance US and EU 7
Slide 8: Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC) A high unmet medical need Among all Lung Cancers Low survival rate at 5 years Limited treatment options in both the US and Europe SCLC ~15% ✦ Highly aggressive tumour ~ 62,000 in 20202 ✦ 5-year survival rate 5-10%1 ~ 30,000 in 20202 Newly diagnosed patients each year 1.
Slide 9: Zepzelca (Lurbinectedin) – The Extensive Stage SCLC Treatment Paradigm
Zepzelca (Lurbinectedin) – The Extensive Stage SCLC Treatment Paradigm Strong positioning opportunity 1st line 1st line Subsequent Therapy Subsequent Therapy Induction Maintenance Induction Maintenance Subsequent Therapy • Platinum/ Etoposide + • Platinum/ Etoposide + • Atezolizumab • Atezolizumab •
Slide 10: Potential practice changing 1st line-Maintenance in SCLC
Potential practice changing 1st line-Maintenance in SCLC 10
Slide 11: Lurbinectedin: First-line maintenance positioning
Lurbinectedin: First-line maintenance positioning Phase 3 trial for first line-maintenance SCLC Induction Phase Maintenance Phase Atezolizumab 1,200 mg q3wk + lurbinectedin 3.2 mg/m2 q3wk Endpoints: Atezolizumab + ✦ Extensive-stage carboplatin + Randomization ≥SD Co-Primary: SCLC (ES-SCLC) Etoposide
Slide 12: Positive results from the IMforte Phase 3 clinical trial
Positive results from the IMforte Phase 3 clinical trial. Statistically significant and clinically meaningful OS & PFS benefit 12
Slide 13: Positive results from the IMforte Phase 3 clinical trial
Positive results from the IMforte Phase 3 clinical trial. Statistically significant and clinically meaningful OS & PFS benefit 13
Slide 14: Positive results from the IMforte Phase 3 clinical trial: safety summary
Positive results from the IMforte Phase 3 clinical trial. Safety summary during the maintenance phase 14
Slide 15: IMforte: All-cause AEs with incidence ≥10%
Positive results from the IMforte Phase 3 clinical trial. All-cause AEs with incidence ≥10% in either arm 15
Slide 16: Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA
Zepzelca: Pathway to 2nd line in SCLC by EMA and Full Approval by FDA Phase 3 (LAGOON) randomized trial. Recruitment ended December 2024. Arm A Lurbinectedin 3.2 mg/m2 every 3 weeks Primary Endpoint: ✦ Relapsed SCLC Arm B ✦ One prior platinum Randomization Overall Survival containing regimen 1:1:1 A
Slide 17: Lurbinectedin. Pathway to market in EU
Lurbinectedin. Pathway to market in EU Key events 2024 2025 2026 2027 2028 IMforte trial 1Q: End of 1H: Expected EU Lurbinectedin + atezolizumab recruitment 1H: Regulatory marketing submission authorization Market access 1st line maintenance 4Q: Positive results SCLC of PFS and OS 2H: Market launch
Slide 18: Lurbinectedin: Commercial outlook
Lurbinectedin: Commercial outlook Global presence European Union Rest of the world PHM territories Partner territories • Western EU. US and rest of the word Commercial agreements • UK, Scandinavia and Eastern Europe: Inmedica Pharma • Greece, Cyprus and Balkans: Genesis Pharma 18
Slide 19: Lurbinectedin - European incidence SCLC in EU10
Lurbinectedin - European incidence SCLC in EU10 Total lung cancer incidence in Europe 484,306 patients (1) SCLC 13%-15% NSCLC 87% 62,960 patients 421,346 patients Population Lung Cancer SCLC Country / Area (2022) Incidence incidence(3) (million) (2022) Germany 83.8 62,025 8,063 Italy 59.0 43,808 5,6
Slide 20: Leiomyosarcoma
Q ZEPZELCA (lurbinectedin) Leiomyosarcoma 20
Slide 21: Leiomyosarcoma: Incidence and treatment paradigm
Leiomyosarcoma Incidence and treatment paradigm One of the most common soft tissue sarcomas (STS) accounting for ~ 10%-20% of all STS Incidence ~2,100(1) in USA Incidence and ~4,500in Europe 1st Line 2nd Line 1st Line 2nd Line FDA ✦ Doxorubicin ✦ Trabectedin EMA ✦ Doxorubicin ✦ Trabectedin Approved
Slide 22: Zepzelca (lurbinectedin)-Leiomyosarcoma
Zepzelca (lurbinectedin)-Leiomyosarcoma Phase III adaptive trial • Metastatic Doxorubicin* 50 mg/m2 + Lurbinectedin 2.2 mg/m2 Uterine/ST LMS + G-CSF D1 q3wk • Measurable disease • No prior chemo Primary endpoint: • ECOG 0-1 PFS by IRC 1:1:1 Doxorubicin* 25 mg/m2 + Lurbinectedin 3.2 mg/m2 Up to ~ 450
Slide 23: Clinical development
Clinical development Key pillars for sustainable growth 2025 2026 2027 2028 Ecubectedin & PM54 • Potential 2nd generation of Lurbinectedin • Novel active transcription inhibitors • Early signs of activity in solid tumors Phase I Phase II Phase III • Good safety profile • Synergy in combination with
Slide 24: Financials
Financials Profitable and solid and stable financial position Robust cash position (€ mn) Total revenues by product(€ mn) 2023 2024 1% 29% 31% €158.2 €174.9 216,5 231,8 212,6 168,6 157,0 70% 69% 21,3 Zepzelca Yondelis Other Zepzelca Yondelis -53,0 -45,6 -39,0 -39,9 -47,8 -82,7 2023 Zepzelca (€mn) 20
Slide 25: Key Events
Key Events Catalyst Calendar Positive IMforte PFS & OS top line data ✓ Lurbinectedin approval in China ✓ End of recruitment LAGOON ✓ Regulatory submission IMforte US ✓ Regulatory submission IMforte EU ✓ Potential out-license (Japan) ✓ Approval lurbinectedin in US ✓ Potential lurbinectedin approvals
Slide 26: www.pharmamar.com
www.pharmamar.com 26